Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 9;10(6):e200164.
doi: 10.1212/NXI.0000000000200164. Print 2023 Nov.

Multiple Sclerosis, Disease-Modifying Therapies, and Infections

Annette M Langer-Gould  1 , Jessica B Smith  2 , Edlin G Gonzales  2 , Fredrik Piehl  2 , Bonnie H Li  2
Affiliations

Multiple Sclerosis, Disease-Modifying Therapies, and Infections

Annette M Langer-Gould et al. Neurol Neuroimmunol Neuroinflamm. .

Abstract

Background and objectives: The use of highly effective multiple sclerosis (MS) disease-modifying therapies (DMTs) is rapidly increasing. Yet, little is known about their real-world risks of infections. The goals of this study were to assess the comparative risk of outpatient and serious infections across DMTs in a large, diverse, U.S. cohort and determine whether such risks are attributable to DMTs, having MS, or other factors.

Methods: We conducted a retrospective cohort study of Kaiser Permanente Southern California members from 2008 through 2020 with MS and non-MS controls matched on age, sex, race, and ethnicity. MS treatments, serious (those requiring hospitalization) and outpatient infections, and covariates were collected from the electronic health record. Adjusted hazard ratios (aHR) and risk ratios (aRR) were estimated using the Cox and Poisson regression, respectively.

Results: Six thousand, six hundred and twenty-six patients with MS with 11,929 treatment episodes (2,487 rituximab, 546 natalizumab, 298 fingolimod, 4,629 interferon-beta/glatiramer acetate, IFN/GLAT, and 3,969 untreated) and 33,550 population controls were included in the analyses. The average age at treatment start ranged from 38.9 to 49.2 years, and 74% were women. Untreated (aRR = 1.39, [95% CI = 1.35-1.44]) and IFN/GLAT-treated patients with MS (aRR = 1.60, [95% CI = 1.56-1.65]) had a higher risk of outpatient infections and serious infections (aHR = 2.97, [95% CI = 2.65-3.32 and aHR = 2.31, [95% CI = 2.04-2.62], respectively) compared with controls. Rituximab (aRR = 1.19, [95% CI = 1.14-1.25]), fingolimod (aRR = 1.22, [95% CI = 1.09-1.37]), and to a lesser extent, natalizumab treatment (aRR = 1.08, [95% CI = 0.97-1.20]) were associated with an increased risk of outpatient infections compared with IFN/GLAT. Rituximab (aHR = 1.41, [95% CI = 1.09-1.84]) and natalizumab (aHR = 1.40, [95% CI = 0.96-2.04]) treatment were associated with a similar increased risk of serious infections compared with IFN/GLAT. The only treatment-specific association identified was fingolimod with outpatient herpetic infections. Higher comorbidity index, previous hospitalization for infections, and advanced disability significantly increased the risk of serious infections independent of DMTs. Hospitalization for UTI-related pseudorelapses accounted for 24%-48% of serious infections.

Discussion: Patients with MS have higher risks of outpatient and serious infections compared with patients without MS. The risk of outpatient infections was similarly increased by rituximab and fingolimod and serious infections by rituximab and natalizumab compared with IFN/GLAT. Steps to minimize risks include optimizing bladder care, comorbidity prevention, varicella vaccination, and considering discontinuing or avoiding DMT use in patients with advanced disability and/or previous hospitalizations for infections.

PubMed Disclaimer

Conflict of interest statement

A. Langer-Gould has received grant support and awards from the Patient-Centered Outcomes Research Institute and the National MS Society. She currently serves as a voting member on the California Technology Assessment Forum, a core program of the Institute for Clinical and Economic Review (ICER). She has received sponsored and reimbursed travel from ICER; F. Piehl has received research grants from Merck KGaA and UCB and fees for serving on DMC in clinical trials with Chugai, Lundbeck, and Roche; J.B. Smith reports no disclosures relevant to the manuscript; E.G. Gonzales reports no disclosures relevant to the manuscript; and B.H. Li reports no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

References

    1. Luna G, Alping P, Burman J, et al. . Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184-191. doi:10.1001/jamaneurol.2019.3365 - DOI - PMC - PubMed
    1. Otero-Romero S, Sanchez-Montalva A, Vidal-Jordana A. Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Rev Clin Immunol. 2021;17(3):285-300. doi:10.1080/1744666x.2021.1886924 - DOI - PubMed
    1. Prosperini L, Haggiag S, Tortorella C, Galgani S, Gasperini C. Age-related adverse events of disease-modifying treatments for multiple sclerosis: a meta-regression. Mult Scler. 2021;27(9):1391-1402. doi:10.1177/1352458520964778 - DOI - PubMed
    1. Persson R, Lee S, Ulcickas Yood M, et al. . Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord. 2020;41:101982. doi:10.1016/j.msard.2020.101982 - DOI - PubMed
    1. Castelo-Branco A, Chiesa F, Conte S, et al. . Infections in patients with multiple sclerosis: a national cohort study in Sweden. Mult Scler Relat Disord. 2020;45:102420. doi:10.1016/j.msard.2020.102420 - DOI - PubMed